Cara Therapeutics | CARA - Current Liabilities


Cara Therapeutics reported $11.04M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 305.52M 28.41M Mar/2026
Alterity Therapeutics Limited AUD 1.73M 2.77M Dec/2025
Cara Therapeutics USD 11.04M 2K Dec/2025
Cassava Sciences USD 40.11M 3.72M Mar/2026
Chugai Pharma JPY 327.7B 83.38B Mar/2026
Cipla INR 70.14B 7.16B Mar/2026
Clal Biotechnology ILS 6.66M 3.75M Dec/2023
Compugen USD 22.04M 533K Mar/2026
CSL USD 4.61B 207M Dec/2025
Grifols EUR 2.37B 156.97M Dec/2025
Halozyme Therapeutics USD 363.21M 186.12M Mar/2026
J&J USD 57.72B 3.59B Mar/2026
Neurocrine Biosciences USD 831.7M 88.3M Mar/2026
Pacira USD 108.79M 11.8M Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
RedHill Biopharma USD 19.22M 3.07M Dec/2025
Supernus Pharmaceuticals USD 373.93M 35.76M Mar/2026
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025